Almir Ribeiro da Silva Junior

Mr. Almir Ribeiro da Silva Junior

Infectious and Parasitic Diseases, Universidade de São Paulo, São Paulo, Brazil
orcid
Master of Science at University of São Paulo

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
LHLayla Honorato
Layla Honorato
SWSteven S. Witkin
Steven S. Witkin
MMMaria Cássia Mendes-Correa
Maria Cássia Mendes-Correa
ATAna Luiza Castro Conde Toscano
Ana Luiza Castro Conde Toscano
ILIara Moreno Linhares
Iara Moreno Linhares
TTTania Regina Tozetto-Mendoza
Tania Regina Tozetto-Mendoza
Introduction: Torque teno virus (TTV) is a non-pathogenic virus present in body fluids. Its titer in the circulation increases in association with immune suppression, such as in HIV-infected individuals. We evaluated if the TTV titer in saliva from HIV-positive individuals undergoing antiretroviral therapy (ART) was related to the circulating CD4+ T lymphocyte concentration and the HIV titer.Methods: Saliva was collected from 276 asymptomatic individuals undergoing ART, and an additional 48 individuals positive for AIDS-associated Kaposi's Sarcoma (AIDS-KS). The salivary TTV titer was measured by gene amplification analysis. The circulating CD4+ T lymphocyte and HIV levels were obtained by chart review.Results: TTV was detectable in saliva from 80% of the asymptomatic subjects and 87% of those with AIDS-KS. In the asymptomatic group the median log10 TTV titer/ml was 3.3 in 200 males vs. 2.4 in 76 females (p < 0.0001). TTV titer/ml was 3.7 when HIV was acquired by intravenous drug usage, 3.2 when by sexual acquisition and 2.4 when blood transfusion acquired. The salivary TTV titer was inversely correlated with the circulating CD4+ T lymphocyte level (p < 0.0001) and positively correlated with the circulating HIV concentration (p = 0.0005). The median salivary TTV titer and circulating HIV titer were higher, and the CD4+ count was lower, in individuals positive for AIDS-KS than in the asymptomatic subjects (p < 0.0001).Conclusion: The TTV titer in saliva is a potential biomarker for monitoring immune status in individuals undergoing ART.

16 June 2022 in Clinics
Verified
Journal Article
Open access
LVLucy Santos Villas-Boas
Lucy Santos Villas-Boas
APAnderson Vicente de Paula
Anderson Vicente de Paula
Almir Ribeiro da Silva JuniorAlmir Ribeiro da Silva Junior
Almir Ribeiro da Silva Junior
HPHeuder Gustavo Oliveira Paiao
Heuder Gustavo Oliveira Paiao
TTTania Regina Tozetto-Mendoza
Tania Regina Tozetto-Mendoza
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 strain that was dominant at the beginning of the pandemic or by the Gamma variant was effective against the Omicron variant. Convalescent sera from 109 individuals, never exposed to a SARS-CoV-2 vaccine, who had mild or moderate symptoms not requiring hospitalization following either a documented SARS-CoV-2 ancestral strain infection or a Gamma variant infection, were assayed for in vitro neutralizing antibody activity against their original strains and the Omicron variant. Following an infection with the ancestral strain, 56 (93.3%), 45 (77.6%) and 1 (1.7%) serum sample were positive for neutralizing antibodies against the ancestral, Gamma variant, and Omicron variant, respectively. After infection with the Gamma variant, 43 (87.8%) and 2 (4.1%) sera were positive for neutralizing antibodies against the Gamma and Omicron variants, respectively. Neutralizing antibodies generated following mild or moderate infection with the SARS-CoV-2 ancestral strain or the Gamma variant are not protective against the Omicron variant.

1 January 2022 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
Almir Ribeiro da Silva JuniorAlmir Ribeiro da Silva Junior
Almir Ribeiro da Silva Junior
LVLucy Santos Villas-Boas
Lucy Santos Villas-Boas
TTTania Regina Tozetto-Mendoza
Tania Regina Tozetto-Mendoza
LHLayla Honorato
Layla Honorato
APAnderson de Paula
Anderson de Paula
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
Vaccination is a fundamental tool to prevent SARS-CoV-2 infection and to limit the COVID-19 pandemic. The emergence of SARS-CoV-2 variants with multiple mutations has raised serious concerns about the ability of neutralizing antibody responses elicited by prior vaccination to effectively combat these variants. The neutralizing capacity against the Gamma, Delta and Omicron variants of sera from individuals immunized with the CoronaVac vaccine remains incompletely determined. The present study evaluated 41 health care workers at the Faculdade de Medicina of the Universidade de Sao Paulo, in Sao Paulo, Brazil, naive to previous SARS- CoV-2 infection, who were vaccinated with two doses of the CoronaVac SARS-CoV-2 vaccine 28 days apart. Neutralizing antibody levels against the Gamma, Delta, and Omicron variants were measured at 32 and 186 days after the second vaccination. We also measured neutralizing antibodies against Omicron in 34 of these individuals following a subsequent booster immunization with the Pfizer vaccine. Quantification of neutralizing antibodies was performed using the Cytopathic Effect-based Virus Neutralization test. Neutralization antibody activity against the Gamma, Delta and Omicron variants was observed in 78.0%, 65.9% and 58.5% of serum samples, respectively, obtained at a mean of 32 days after the second immunization. This decreased to 17.1%, 24.4% and 2.4% of sera having activity against Delta, Gamma and Omicron, respectively, at 186 days post-vaccination. The median neutralizing antibody titers at 32 days were 1:40, 1:20 and 1:20 against Gamma, Delta and Omicron, respectively, and decreased to an undetectable median level against all variants at the later time. A booster immunization with the Pfizer vaccine elicited neutralizing antibodies against Omicron in 85% of subjects tested 60 days after vaccination. We conclude that two doses of the CoronaVac vaccine results in limited protection of short duration against the Gamma, Delta and Omicron SARS-CoV-2 variants. A booster dose with the Pfizer vaccine induced antibody neutralizing activity against Omicron in most patients which was measurable 60 days after the booster.

29 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
MSMatias Chiarastelli Salomao
Matias Chiarastelli Salomao
FGFábio Ghilardi
Fábio Ghilardi
TTTania Regina Tozetto-Mendoza
Tania Regina Tozetto-Mendoza
LVLucy Santos Villas-Boas
Lucy Santos Villas-Boas
SWSteven Witkin
Steven Witkin
Introduction—The dynamics of SARS-CoV-2 shedding and replication in humans remain incompletely understood. Methods—We analyzed SARS-CoV-2 shedding from multiple sites in individuals with an acute COVID-19 infection by weekly sampling for five weeks in 98 immunocompetent and 25 immunosuppressed individuals. Samples and culture supernatants were tested via RT-PCR for SARS-CoV-2 to determine viral clearance rates and in vitro replication. Results—A total of 2447 clinical specimens were evaluated, including 557 nasopharyngeal swabs, 527 saliva samples, 464 urine specimens, 437 anal swabs and 462 blood samples. The SARS-CoV-2 genome sequences at each site were classified as belonging to the B.1.128 (ancestral strain) or Gamma lineage. SARS-CoV-2 detection was highest in nasopharyngeal swabs regardless of the virus strain involved or the immune status of infected individuals. The duration of viral shedding varied between clinical specimens and individual patients. Prolonged shedding of potentially infectious virus varied from 10 days up to 191 days, and primarily occurred in immunosuppressed individuals. Virus was isolated in culture from 18 nasal swab or saliva samples collected 10 or more days after onset of disease. Conclusions—Our findings indicate that persistent SARS-CoV-2 shedding may occur in both competent or immunosuppressed individuals, at multiple clinical sites and in a minority of subjects is capable of in vitro replication.

22 September 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ALAlessandra Luna-Muschi
Alessandra Luna-Muschi
SNSaidy Vásconez Noguera
Saidy Vásconez Noguera
IBIgor C Borges
Igor C Borges
APAnderson V De Paula
Anderson V De Paula
MCMarina Farrel Côrtes
Marina Farrel Côrtes
SCSilvia Figueiredo Costa
Silvia Figueiredo Costa
In this prospective cohort of 30 vaccinated healthcare workers with mild Omicron variant infection, we evaluated viral culture, rapid antigen test (RAT), and real-time reverse-transcription polymerase chain reaction (RT-PCR) of respiratory samples at days 5, 7, 10, and 14. Viral culture was positive in 46% (11/24) and 20% (6/30) of samples at days 5 and 7, respectively. RAT and RT-PCR (Ct ≤35) showed 100% negative predictive value (NPV), with positive predictive values (PPVs) of 32% and 17%, respectively, for predicting viral culture positivity. A lower RT-PCR threshold (Ct ≤24) improved culture prediction (PPV = 39%; NPV = 100%). Vaccinated persons with mild Omicron infection are potentially transmissible up to day 7. RAT and RT-PCR might be useful tools for shortening the isolation period.

20 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTTania Regina Tozetto-Mendoza
Tania Regina Tozetto-Mendoza
MMMaria C. Mendes-Correa
Maria C. Mendes-Correa
AMAntonio F. Moron
Antonio F. Moron
LFLarry J. Forney
Larry J. Forney
ILIara M. Linhares
Iara M. Linhares
SWSteven S. Witkin
Steven S. Witkin
Torquetenovirus (TTV) is a nonpathogenic endogenous virus whose abundance varies with the extent of immune system activation. We determined if the TTV titer in the vagina of pregnant women was associated with vaginal microbiota composition and levels of compounds in vaginal secretions. Vaginal TTV and microbiota composition in 494 second trimester pregnant women were identified by gene amplification and analysis. Vaginal matrix metalloproteinases (MMPs), tissue inhibitors of MMP (TIMP) and lactic acid isomers were measured by ELISA. Dominance was defined as the relative abundance of a specific bacterium or species at >50% of the total number of bacteria identified. Clinical data were obtained by chart review. The median log10TTV titer was lowest whenLactobacillusspecies other thanL.inerswere dominant (<1.0) as compared to whenL.iners(4.1, p = 0.0001), bacteria other than lactobacilli (4.5, p = 0.0016) or no bacterium (4.7, p = 0.0009) dominated. The TTV titer was inversely proportional toL.crispatusabundance (p<0.0001) and directly proportional to levels ofG.vaginalis(p = 0.0008) andL.iners(p = 0.0010). The TTV titer was proportional to TIMP-1, TIMP-2, MMP-8 and MMP-9 abundance (p≤0.0002) and inversely proportional to the level of D-lactic acid (p = 0.0024). We conclude that the association between variations in the TTV titer and the relative abundance of specific bacterial species and vaginal compounds indicates that local changes in immune status likely influence vaginal fluid composition.